CoChat

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration

Open access
Vedula, Satyanarayana S, Krzystolik, Magdalena · 2008 · Cochrane Database of Systematic Reviews
Cited by 87

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Age-related macular degeneration (AMD) is a common cause of severe vision loss in people 55 years and older. OBJECTIVES: The objective of this review was to investigate the effects of anti-VEGF (vascular endothelial growth factor) modalities for treating neovascular AMD. SEARCH STRATEGY: We searched CENTRAL, MEDLINE, EMBASE and LILACS. We handsearched ARVO abstracts for 2006, 2007 for ongoing trials. SELECTION CRITERIA: We included randomized controlled trials (RCTs). DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data. We contacted trial authors for additional data. We summarized outcomes as relative risks (RR), number needed to treat (NNT) and weighted mean differences. MAIN RESULTS: We included five RCTs of good methodological quality. All five trials were conducted by pharmaceutical companies. An intention-to-treat analysis using the last observation carried forward method was done in most trials. Two trials compared pegaptanib versus sham. One trial compared ranibizumab versus sham, another compared ranibizumab/sham verteporfin PDT versus verteporfin PDT/sham ranibizumab, and the final trial compared ranibizumab plus verteporfin PDT versus verteporfin PDT alone. Fewer patients treated with pegaptanib lost 15 or more letters of visual acuity at one year follow-up compared to sham (pooled relative risk (RR) 0.71; 95% confidence interval (CI) 0.61 to 0.84). The NNT was 6.67 (95% CI 4.35 to 14.28) for 0.3 mg pegaptanib, 6.25 (95% CI 4.17 to 12.5) for 1 mg pegaptanib and 14.28 (95% CI 6.67 to 100) for 3 mg pegaptanib. In a trial of ranibizumab versus sham, RR for loss of 15 or more letters visual acuity at one year was 0.14 (95% CI 0.1 to 0.22) in favour of ranibizumab. The NNT was 3.13 (95% CI 2.56 to 3.84) for 0.3 mg ranibizumab and 3.13 (95% CI 2.56 to 3.84) for 0.5 mg ranibizumab. In a trial of ranibizumab versus verteporfin PDT, RR for loss of 15 or more letters at one year was 0.13 (95% CI 0.07 to 0.23) favouring ranibizumab. The NNT was 3.33 (95% CI 2.56 to 4.76) for 0.3 mg ranibizumab and 3.12 (95% CI 2.43 to 4.17) for 0.5 mg ranibizumab. In another trial of combined ranibizumab plus verteporfin PDT versus verteporfin PDT, RR for loss of 15 or more letters at one year favoured combined therapy (RR 0.3 (95% CI 0.15 to 0.60). The NNT was 4.35 (95% CI 2.78 to 11.11). Pooled RR for gain of 15 or more letters visual acuity at one year was 5.81 (95% CI 3.29 to 10.26) for ranibizumab versus sham, 6.79 (95% CI 3.41 to 13.54) for ranibizumab/sham verteporfin PDT versus verteporfin PDT/sham ranibizumab, and 4.44 (95% CI 1.40 to 14.08) for ranibizumab plus verteporfin PDT versus verteporfin PDT. Frequency of endophthalmitis in included studies was between 0.7% to 4.7% with ranibizumab and 1.3% with pegaptanib. Improvement in vision-specific quality of life was reported for both treatments. AUTHORS' CONCLUSIONS: Pegaptanib and ranibizumab reduce the risk of visual acuity loss in patients with neovascular AMD. Ranibizumab causes gains in visual acuity in many eyes. Quality of life and cost will be important for treatment decisions. Other agents blocking VEGF are being tested in ongoing trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd005139.pub2

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Research works printed but not linked: 62

  1. Apte, 2007, Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration, Ophthalmology, 114, 1702, 10.1016/j.ophtha.2007.02.021 · DOI
  2. Chang, 2007, Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial, Archives of Ophthalmology, 125, 1460, 10.1001/archopht.125.11.1460 · DOI · Paper page
  3. Chang, 2006, Self-reported vision-specific quality of life at 1 year in patients with neovascular age-related macular degeneration in 2 Phase Iii randomized clinical trials of ranibizumab, Investigative Ophthalmology & Visual Science, 47, E-Abstract 5252
  4. Kaiser, 2007, Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration, Ophthalmology, 114, 1868, 10.1016/j.ophtha.2007.04.030 · DOI · Paper page
  5. Aggio, 2006, Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration, Acta Ophthalmologica Scandinavica, 84, 831, 10.1111/j.1600-0420.2006.00764.x · DOI
  6. Barouch, 2004, Anti-vascular endothelial growth factor strategies for the treatment of choroidal neovascularization from age-related macular degeneration, International Ophthalmology Clinics, 44, 23, 10.1097/00004397-200404430-00005 · doi:10.1097/00004397-200404430-00005
  7. Bashshur, 2007, Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration, Archives of Ophthalmology, 125, 1357, 10.1001/archopht.125.10.1357 · DOI
  8. 2003, Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results, Ophthalmology, 110, 979, 10.1016/S0161-6420(03)00085-X · DOI · Paper page
  9. Fine, 2005, Pegaptanib sodium, Nature Reviews. Drug Discovery, 4, 187, 10.1038/nrd1677 · DOI
  10. Hahn, 2007, Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration, Der Ophthalmologe : Zeitschrift Der Deutschen Ophthalmologischen Gesellschaft, 104, 588, 10.1007/s00347-007-1547-4 · DOI
  11. Heier, 2006, Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study, Ophthalmology, 113, 642. e1-4, 10.1016/j.ophtha.2005.10.052 · DOI · Paper page
  12. Kim, 2004, Innovative treatments for exudative age-related macular degeneration, International Ophthalmology Clinics, 44, 41, 10.1097/00004397-200404440-00005 · DOI
  13. Lazic, 2007, Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration, Ophthalmology, 114, 1179, 10.1016/j.ophtha.2007.03.006 · DOI
  14. Michels, 2005, Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study, Ophthalmology, 112, 1035, 10.1016/j.ophtha.2005.02.007 · DOI · Paper page
  15. Nguyen, 2006, A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration, Ophthalmology, 113, 1522.e1, 10.1016/j.ophtha.2006.05.055 · DOI
  16. Rakic, 2005, Pegaptanib and age-related macular degeneration, New England Journal of Medicine, 352, 1720, 10.1056/NEJM200504213521619 · DOI
  17. Razavi, 2002, Age-related macular degeneration: A review of anti-angiogenic treatments, Journal Francais D'Ophtalmologie, 25, 747
  18. Rosenfeld, 2005, Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration, Ophthalmology, 112, 1048, 10.1016/j.ophtha.2005.01.043 · DOI · Paper page
  19. Scott, 2007, Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study - Commentary, Evidence-Based Ophthalmology, 8, 100
  20. Siddiqui, 2005, Pegaptanib in exudative age-related macular degeneration, Drugs, 65, 1571, 10.2165/00003495-200565110-00010 · DOI
  21. Campochiaro, 2004, Ocular neovascularization and excessive vascular permeability, Expert Opinion on Biological Therapy, 4, 1395, 10.1517/14712598.4.9.1395 · DOI · Paper page
  22. Michels, 2005, Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis, Klinische Monatsblatter Fur Augenheilkunde, 222, 480, 10.1055/s-2005-858315 · doi:10.1055/s-2005-858315
  23. Mills, 2007, A randomized trial of Pegaptanib sodium for age-related macular degeneration used an innovative design to explore disease-modifying effects, Journal of Clinical Epidemiology, 60, 456, 10.1016/j.jclinepi.2006.09.001 · DOI
  24. Moshfeghi, 2005, Pegaptanib sodium for the treatment of neovascular age-related macular degeneration, Expert Opinion on Investigational Drugs, 14, 671, 10.1517/13543784.14.5.671 · DOI
  25. Ng, 2005, Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration, Canadian Journal of Ophthalmology, 40, 352, 10.1016/S0008-4182(05)80078-X · DOI · Paper page
  26. Pulido, 2002, Multicenter prospective, randomized, double-masked, placebo-controlled study of rheopheresis to treat neovascular age-related macular degeneration: Interim analysis, Transactions of the American Ophthalmological Society, 100, 85
  27. Pulido, 2005, Rheopheresis for age-related macular degeneration: clinical results and putative mechanism of action, Canadian Journal of Ophthalmology, 40, 332, 10.1016/S0008-4182(05)80076-6 · DOI
  28. Sorbera, 2003, Ranibizumab: Treatment of age-related macular degeneration humanized monoclonal anti-VEGF antibody angiogenesis inhibitor, Drugs of the Future, 28, 541, 10.1358/dof.2003.028.06.738510 · doi:10.1358/dof.2003.028.06.738510
  29. Aiello, 1994, Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders, New England Journal of Medicine, 331, 1480, 10.1056/NEJM199412013312203 · DOI · Paper page
  30. Avery, 2006, Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration, Ophthalmology, 113, 367, 10.1016/j.ophtha.2005.11.019 · DOI · Paper page
  31. Blinder, 2003, Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1, American Journal of Ophthalmology, 136, 407
  32. Boekhoorn, 2007, C-reactive protein level and risk of aging macula disorder: The Rotterdam Study, Archives of Ophthalmology, 125, 1396, 10.1001/archopht.125.10.1396 · DOI · Paper page
  33. Brown, 2007, Anti-VEGF agents in the treatment of age-related macular degeneration: applying clinical trial results to the treatment of everyday patients, American Journal of Ophthalmology, 144, 627, 10.1016/j.ajo.2007.06.039 · DOI · Paper page
  34. Brown, 2007, A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration, Ophthalmology, Oct 31 (Epub ah
  35. Bunce, 2006, Leading causes of certification for blindness and partial sight in England & Wales, BMC Public Health, 6, 58, 10.1186/1471-2458-6-58 · DOI · Paper page
  36. Deangelis, 2007, Cigarette smoking, CFH, APOE, ELOVL4, and risk of neovascular age-related macular degeneration, Archives of Ophthalmology, 125, 49, 10.1001/archopht.125.1.49 · DOI · Paper page
  37. Deeks JJ Higgins JPT Altman DG Analysing and presenting data. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006; Section 8] In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd
  38. Emerson, 2007, Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration, Retina, 27, 439, 10.1097/IAE.0b013e31804b3e15 · DOI · Paper page
  39. Fung, 2007, An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration, American Journal of Ophthalmology, 143, 566, 10.1016/j.ajo.2007.01.028 · DOI · Paper page
  40. Ghafour, 1983, Common causes of blindness and visual handicap in the west of Scotland, British Journal of Ophthalmology, 67, 209, 10.1136/bjo.67.4.209 · DOI · Paper page
  41. Glanville, 2006, How to identify randomized controlled trials in MEDLINE: ten years on, Journal of the Medical Library Association, 94, 130
  42. Higgins JPT Green S Assessment of study quality. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Section 6 In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd
  43. Hyman, 1987, Epidemiology of eye disease in the elderly, Eye, 1, 330, 10.1038/eye.1987.53 · DOI
  44. Jager RD. Aiello, 2004, Risks of intravitreous injection: A comprehensive review, Retina, 24, 676, 10.1097/00006982-200410000-00002 · DOI · Paper page
  45. Klein, 2008, Further observations on the association between smoking and the long-term incidence and progression of age-related macular degeneration, Archives of Ophthalmology, 126, 115, 10.1001/archopht.126.1.115 · DOI · Paper page
  46. Kvanta, 1996, Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor, Investigative Ophthalmology & Visual Science, 37, 1929
  47. Leibowitz, 1980, The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975, Survey of Ophthalmology, 24, 335
  48. Lopez, 1996, Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes, Investigative Ophthalmology and Visual Science, 37, 855
  49. Mitchell, 2002, Smoking and the 5-year incidence of age-related maculopathy: the Blue Mountains Eye Study, Archives Ophthalmology, 120, 1357, 10.1001/archopht.120.10.1357 · DOI · Paper page
  50. 1991, Argon laser photocoagulation for neovascular maculopathy Five-year results from randomized clinical trials Macular Photocoagulation Study Group, Archives of Ophthalmology, 109, 1109, 10.1001/archopht.1991.01080080069030 · DOI · Paper page
  51. O'Shea, 1998, Age-related macular degeneration, Postgraduate Medical Journal, 74, 203, 10.1136/pgmj.74.870.203 · DOI
  52. Piguet, 1993, Age-related Bruch's membrane change: a clinical study of the relative role of heredity and environment, British Journal Ophthalmology, 77, 400, 10.1136/bjo.77.7.400 · DOI · Paper page
  53. Raftery, 2007, Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness, British Journal of Ophthalmology, 91, 1244, 10.1136/bjo.2007.116616 · DOI · Paper page
  54. Schaumberg, 2007, A prospective study of 2 major age-related macular degeneration susceptibility alleles and interactions with modifiable risk factors, Archives of Ophthalmology, 125, 55, 10.1001/archopht.125.1.55 · DOI · Paper page
  55. Silvestri, 1994, Is genetic predisposition an important risk factor in age-related macular degeneration?, Eye, 8, 564, 10.1038/eye.1994.138 · DOI
  56. Spaide, 2006, Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration, Retina, 26, 383, 10.1097/00006982-200604000-00001 · DOI · Paper page
  57. Solomon, 2007, Incident choroidal neovascularization in fellow eyes of patients with unilateral subfoveal choroidal neovascularization secondary to age-related macular degeneration: SST report No. 20 from the Submacular Surgery Trials Research Group, Archives of Ophthalmology, 125, 1323, 10.1001/archopht.125.10.1323 · DOI · Paper page
  58. 1999, Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report, Archives of Ophthalmology, 117, 1329, 10.1001/archopht.117.10.1329 · DOI · Paper page
  59. Tielsch, 1994, Vision problems in the US: a report on blindness and vision impairment in adults age 40 and older
  60. Kerckhoven, 2001, Features of age-related macular degeneration on optical coherence tomography, Bulletin de la Societe Belge d' Ophtalmologie, 281, 75
  61. Virgili, 2007, Laser photocoagulation for neovascular age-related macular degeneration, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004763.pub2 · DOI
  62. Wormald, 2007, Photodynamic therapy for nonvascular age-related macular degeneration, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD002030.pub3 · DOI · Paper page

Cited by

See all 87

Metadata

Authors
Vedula, S. S., & Krzystolik, M.
Venue
Cochrane Database of Systematic Reviews
Published
2008-04-23
Issue
2
Pages
CD005139-CD005139
ISSN
1361-6137 (ISSN-L)
OpenAlex
W1553160311
Cited by
87
References
20
Type
reference entry
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. https://app.cochat.ai/papers/10.1002/14651858.cd005139.pub2
The paper
Vedula, S. S., & Krzystolik, M. (2008). Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd005139.pub2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.